ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, today announced that members of its senior management team are scheduled to participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 12:30 p.m. ET. The presentation will feature a business overview and update by Ken Drazan, MD, ArsenalBio’s Chairman and Chief Executive Officer.
A live webcast of the event will be available here. A replay of the webcast will be available at the same location for 90 days following the presentation.
ArsenalBio is a privately held, programmable cell therapy company focused on the realization of solid tumor cell therapy by helping more patients fight cancer and saving lives. Its discovery engine comprises precise genome editing using CRISPR-enabled CITE, integrated circuits incorporating its PrimeR™ logic gates and therapeutic enhancements from its CARchitecture™ library, enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. To learn more, visit www.arsenalbio.com and follow us on Twitter @ArsenalBio, LinkedIn and Facebook.
Heidi Chokeir, Ph.D.